Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bojan Vujkovac

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
The American Journal of Case Reports|June 10, 2017
Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry DiseaseTajda Keber, Martin Tretjak, Andreja Cokan Vujkovac, et al.
Nephron|September 12, 2019
Aging in Fabry Disease: Role of Telomere Length, Telomerase Activity, and Kidney DiseaseAndreja Cokan Vujkovac, Srdjan Novaković, Bojan Vujkovac, et al.
Thrombosis and Haemostasis|January 18, 2006
The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patientsMiso Sabovic, Irena Preloznik Zupan, Barbara Salobir, et al.
Clinical Kidney Journal|February 11, 2022
Podocyturia in Fabry disease: a 10-year follow-upBojan Vujkovac, Irena Srebotnik Kirbiš, Tajda Keber, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|January 29, 2011
Association between platelet-related hemostasis impairment and functional iron deficiency in hemodialysis patientsIrena P Zupan, Miso Sabovic, Barbara Salobir, et al.
Thrombosis and Haemostasis|February 16, 2005
The study of anaemia-related haemostasis impairment in haemodialysis patients by in vitro closure time testIrena Preloznik Zupan, Miso Sabovic, Barbara Salobir, et al.
Genes|August 6, 2021
Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry NephropathyTina Levstek, Teo Mlinšek, Marija Holcar, et al.
Cells|February 12, 2025
Telomere Length, Oxidative Stress, and Kidney Damage Biomarkers in Fabry NephropathyTina Levstek, Erazem Bahčič, Bojan Vujkovac, et al.
Journal of Clinical Medicine|August 26, 2022
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry DiseaseMarkus Cybulla, Kathleen Nicholls, Sandro Feriozzi, et al.
Molecular Genetics and Metabolism|August 4, 2022
An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry diseaseDominique P Germain, Gheona Altarescu, Roberto Barriales-Villa, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
The American Journal of Case Reports|June 10, 2017
Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry DiseaseTajda Keber, Martin Tretjak, Andreja Cokan Vujkovac, et al.
Nephron|September 12, 2019
Aging in Fabry Disease: Role of Telomere Length, Telomerase Activity, and Kidney DiseaseAndreja Cokan Vujkovac, Srdjan Novaković, Bojan Vujkovac, et al.
Thrombosis and Haemostasis|January 18, 2006
The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patientsMiso Sabovic, Irena Preloznik Zupan, Barbara Salobir, et al.
Clinical Kidney Journal|February 11, 2022
Podocyturia in Fabry disease: a 10-year follow-upBojan Vujkovac, Irena Srebotnik Kirbiš, Tajda Keber, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|January 29, 2011
Association between platelet-related hemostasis impairment and functional iron deficiency in hemodialysis patientsIrena P Zupan, Miso Sabovic, Barbara Salobir, et al.
Thrombosis and Haemostasis|February 16, 2005
The study of anaemia-related haemostasis impairment in haemodialysis patients by in vitro closure time testIrena Preloznik Zupan, Miso Sabovic, Barbara Salobir, et al.
Genes|August 6, 2021
Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry NephropathyTina Levstek, Teo Mlinšek, Marija Holcar, et al.
Cells|February 12, 2025
Telomere Length, Oxidative Stress, and Kidney Damage Biomarkers in Fabry NephropathyTina Levstek, Erazem Bahčič, Bojan Vujkovac, et al.
Journal of Clinical Medicine|August 26, 2022
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry DiseaseMarkus Cybulla, Kathleen Nicholls, Sandro Feriozzi, et al.
Molecular Genetics and Metabolism|August 4, 2022
An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry diseaseDominique P Germain, Gheona Altarescu, Roberto Barriales-Villa, et al.
Pageof 4